BR9713239A - Lactamas e imidas heterocìclicas de aralquila e aralquileno - Google Patents

Lactamas e imidas heterocìclicas de aralquila e aralquileno

Info

Publication number
BR9713239A
BR9713239A BR9713239-0A BR9713239A BR9713239A BR 9713239 A BR9713239 A BR 9713239A BR 9713239 A BR9713239 A BR 9713239A BR 9713239 A BR9713239 A BR 9713239A
Authority
BR
Brazil
Prior art keywords
aralkyl
aralkylene
imides
heterocyclic lactams
compounds
Prior art date
Application number
BR9713239-0A
Other languages
English (en)
Inventor
Harry Raph Howard
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR9713239A publication Critical patent/BR9713239A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C07D273/06—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/06—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Patente de Invenção:<B>"LACTAMAS E IMIDAS HETEROCìCLICAS DE ARALQUILA E ARALQUILIDENO"<D>. A presente invenção refere-se a compostos da fórmula em que R^ 1^, R^ 2^, R^ 3^, X,Y, e a linha a tracejado são definidos como na memória, a intermediários para a sua preparação, a composições farmacêuticas que os contêm e ao seu uso medicinal. Tais compostos são úteis como agentes psicoterapêuticos.
BR9713239-0A 1996-09-30 1997-09-08 Lactamas e imidas heterocìclicas de aralquila e aralquileno BR9713239A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2711196P 1996-09-30 1996-09-30
PCT/IB1997/001062 WO1998014433A1 (en) 1996-09-30 1997-09-08 Aralkyl and aralkylidene heterocyclic lactams and imides

Publications (1)

Publication Number Publication Date
BR9713239A true BR9713239A (pt) 2000-04-04

Family

ID=21835752

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9713239-0A BR9713239A (pt) 1996-09-30 1997-09-08 Lactamas e imidas heterocìclicas de aralquila e aralquileno

Country Status (46)

Country Link
US (6) US6380186B1 (pt)
EP (1) EP0929528B1 (pt)
JP (1) JP3121355B2 (pt)
KR (2) KR100323167B1 (pt)
CN (2) CN1093123C (pt)
AP (1) AP769A (pt)
AR (1) AR008861A1 (pt)
AT (1) ATE245630T1 (pt)
AU (1) AU732451B2 (pt)
BG (1) BG64484B1 (pt)
BR (1) BR9713239A (pt)
CA (1) CA2266107C (pt)
CO (1) CO4650135A1 (pt)
CZ (1) CZ295141B6 (pt)
DE (1) DE69723711T2 (pt)
DK (1) DK0929528T3 (pt)
DZ (1) DZ2321A1 (pt)
EA (1) EA002157B1 (pt)
ES (1) ES2202634T3 (pt)
GT (1) GT199700107A (pt)
HK (1) HK1022313A1 (pt)
HN (1) HN1997000135A (pt)
HR (1) HRP970540B1 (pt)
ID (1) ID19833A (pt)
IL (2) IL129045A (pt)
IS (1) IS4985A (pt)
MA (1) MA26443A1 (pt)
MY (1) MY125749A (pt)
NO (1) NO313192B1 (pt)
NZ (1) NZ334215A (pt)
OA (1) OA11002A (pt)
PA (1) PA8439101A1 (pt)
PE (1) PE2799A1 (pt)
PL (1) PL196005B1 (pt)
PT (1) PT929528E (pt)
RS (1) RS49699B (pt)
SA (2) SA05260293B1 (pt)
SI (1) SI0929528T1 (pt)
SK (1) SK284704B6 (pt)
TN (1) TNSN97161A1 (pt)
TR (1) TR199900660T2 (pt)
TW (1) TW491842B (pt)
UA (1) UA56185C2 (pt)
UY (1) UY24730A1 (pt)
WO (1) WO1998014433A1 (pt)
ZA (1) ZA978703B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56185C2 (uk) * 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
US6423708B1 (en) * 1996-09-30 2002-07-23 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides
DE69919436T2 (de) 1998-04-16 2005-09-15 Pfizer Products Inc., Groton N-Acyl und N-Aroyl Aralkylamide
KR20010086073A (ko) * 1998-12-02 2001-09-07 데이비드 존 우드 ｐ53계 단백질의 배좌 안정성을 회복하기 위한 방법 및조성물
EP1041070B1 (en) 1999-03-30 2004-09-22 Pfizer Products Inc. Process for preparing cyclic thioamides
DE10022661A1 (de) * 2000-05-10 2001-11-15 Clariant Gmbh Ortho-substituierte Benzaldehyde, Verfahren zu ihrer Herstellung und ihre Verwendung
UA76130C2 (en) 2000-11-20 2006-07-17 Merck Patent Gmbh Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
WO2002078643A2 (en) * 2001-03-30 2002-10-10 Philadelphia Health And Education Corporation Immunomodulation and effect on cell processes relating to serotonin family receptors
EP1746091A1 (en) * 2001-08-30 2007-01-24 Pfizer Products Inc. Process for the preparation of 2-substituted 2-[-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3-one citrate
ATE332897T1 (de) 2001-08-30 2006-08-15 Pfizer Prod Inc Verfahren zur herstellung von 2-(4-alkyl-1- piperazinyl)-benzaldehyd und -benzylidenyl- derivaten durch nucleophile substitution von 2- fluorobenzaldehyd mit 4-alkyl-1-piperazinen in wasser als lösungsmittel
IL162096A0 (en) * 2001-12-07 2005-11-20 Pfizer Prod Inc Citric acid salt of a therapeutic compound and pharmaceutical compositions thereof
EP1469850B1 (en) 2002-01-02 2013-01-02 Versi Group, LLC Method of treating sexual dysfunctions with delta opioid receptor agonist compounds
US7235573B2 (en) * 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
JP4977319B2 (ja) * 2002-09-30 2012-07-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 嚢胞性線維症膜コンダクタンス制御因子蛋白質阻害薬およびその使用方法
AU2003282920A1 (en) * 2002-10-04 2004-05-04 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
EP1689721B1 (en) * 2003-11-26 2010-07-14 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
WO2005053701A1 (en) * 2003-11-26 2005-06-16 Pfizer Products Inc. Combination of dopamine agonists and aralkyl and aralkylidene heterocyclic lactams and imides
EP1697353A2 (en) * 2003-12-15 2006-09-06 Pfizer Products Incorporated Aralkyl and aralkylidene heterocyclic lactams with affinity for 5-ht1 receptors
US20050171095A1 (en) * 2004-01-06 2005-08-04 Pfizer Inc Combination of CRF antagonists and 5-HT1B receptor antagonists
US20050165025A1 (en) * 2004-01-22 2005-07-28 Recordati Ireland Ltd. Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
EP1737466A1 (en) * 2004-01-29 2007-01-03 Pfizer Products Inc. COMBINATION OF y-AMINOBUTYRIC ACID MODULATORS AND 5-HT-1b RECEPTOR ANTAGONISTS
EA200601461A1 (ru) * 2004-03-17 2007-02-27 Пфайзер Продактс, Инк. Новые производные бензил(иден)лактама
JP4185154B2 (ja) 2004-04-30 2008-11-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 中枢神経系障害治療用の置換モルホリン化合物
BRPI0510942A (pt) * 2004-05-11 2007-07-17 Pfizer Prod Inc combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b
WO2005113535A2 (en) * 2004-05-21 2005-12-01 Pfizer Products Inc. Pyrazinylmethyl lactam derivatives
WO2005113526A2 (en) * 2004-05-21 2005-12-01 Pfizer Products Inc. Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one
WO2006048727A1 (en) * 2004-11-02 2006-05-11 Pfizer Products Inc. Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor
WO2006106416A1 (en) * 2005-04-08 2006-10-12 Pfizer Products Inc. PYRIDIL-LACTAMS AND THEIR USE 5 -HTl RECEPTORS LIGAN
WO2007026224A2 (en) * 2005-08-31 2007-03-08 Pfizer Products Inc. 5-ht1b antagonist composition for depression, anxiety and cognition
WO2007026219A2 (en) * 2005-08-31 2007-03-08 Pfizer Products Inc. Combinations of a 5-ht1b antagonist with a noradrenalin re-uptake inhibitor or a serotonin noradrenalin reutake inhibitor for treating cns conditions
WO2007057742A2 (en) * 2005-11-18 2007-05-24 Pfizer Products Inc. Novel piperazinone derivatives
GB0701970D0 (en) * 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
AU2008299921B2 (en) 2007-09-13 2012-03-01 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
MX2010010343A (es) * 2008-03-25 2010-10-15 Univ California Inhibidores solubles en agua de molecula pequeña del regulador de conductancia transmembrana de fibrosis quistica.
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
EP3029042A1 (en) * 2011-10-03 2016-06-08 Euroscreen S.A. Novel chiral n-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor mediated disorders and chiral synthesis thereof
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
DE102013019618A1 (de) * 2013-11-25 2015-05-28 Avlen Georges Tri- und Tetracyclische Verbindungen zur Behandlung von Inkontinenz
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
CN110054597B (zh) * 2019-04-17 2022-11-08 温州大学 一种无金属催化剂条件下合成的噻唑烷-4-酮衍生物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6229570A (ja) 1985-07-29 1987-02-07 Kanegafuchi Chem Ind Co Ltd ３，５−ジイソプロピルベンジリデン複素環式化合物
HU199134B (en) 1987-12-14 1990-01-29 Richter Gedeon Vegyeszet Process for producing new 2,3-thiomorpholinedine-2-oxime derivatives and pharmaceutical compositions comprising same
IE62214B1 (en) * 1988-05-25 1995-01-11 Warner Lambert Co Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents
US5216002A (en) 1989-12-21 1993-06-01 Eli Lilly And Company Method of treating inflammatory bowel disease
DE4119757A1 (de) * 1991-06-15 1992-12-17 Basf Ag Aminoalkylsubstituierte thiazolin-2-one, ihre herstellung und verwendung
CA2099233A1 (en) * 1992-06-29 1993-12-30 Conrad P. Dorn Morpholine and thiomorpholine tachykinin receptor antagonists
EP0689536B1 (en) * 1993-03-16 2001-05-23 Pfizer Inc. Naphthalene derivatives
US5556841A (en) * 1994-02-04 1996-09-17 Santen Pharmaceutical Co., Ltd. Thiazine or thiomorpholine derivatives
GB9410512D0 (en) * 1994-05-25 1994-07-13 Smithkline Beecham Plc Novel treatment
EP0767782B1 (en) * 1994-06-29 2001-10-31 Pfizer Inc. Aryl and heteroaryl alkoxynaphthalene derivatives
JP3852787B2 (ja) 1995-06-01 2006-12-06 久光製薬株式会社 チオモルホリン誘導体
EP0779282A1 (en) * 1995-12-14 1997-06-18 Eli Lilly And Company Thiomorpholinone compounds for treating multiple sclerosis
UA56185C2 (uk) * 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
US6423708B1 (en) * 1996-09-30 2002-07-23 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides

Also Published As

Publication number Publication date
US20020091117A1 (en) 2002-07-11
BG103297A (en) 1999-11-30
EA002157B1 (ru) 2001-12-24
SA97180449A (ar) 2005-12-03
PT929528E (pt) 2003-12-31
DE69723711D1 (de) 2003-08-28
US6562813B2 (en) 2003-05-13
ID19833A (id) 1998-08-06
CA2266107A1 (en) 1998-04-09
JP3121355B2 (ja) 2000-12-25
US6472388B2 (en) 2002-10-29
CO4650135A1 (es) 1998-09-03
HRP970540A2 (en) 1998-08-31
PL332629A1 (en) 1999-09-27
SA97180449B1 (ar) 2005-12-21
DZ2321A1 (fr) 2002-12-28
US20020091119A1 (en) 2002-07-11
AP769A (en) 1999-09-30
CA2266107C (en) 2002-12-03
ES2202634T3 (es) 2004-04-01
PL196005B1 (pl) 2007-11-30
EP0929528A1 (en) 1999-07-21
MY125749A (en) 2006-08-30
CZ107199A3 (cs) 2000-05-17
SI0929528T1 (en) 2003-10-31
NO313192B1 (no) 2002-08-26
HK1022313A1 (en) 2000-08-04
KR100323167B1 (ko) 2002-02-04
US6403592B1 (en) 2002-06-11
HN1997000135A (es) 1998-01-28
EA199900242A1 (ru) 1999-08-26
TR199900660T2 (xx) 1999-07-21
KR20000048731A (ko) 2000-07-25
CN1239497C (zh) 2006-02-01
HRP970540B1 (en) 2002-08-31
SK284704B6 (sk) 2005-09-08
KR100346620B1 (ko) 2002-07-26
ZA978703B (en) 1999-03-30
SK41099A3 (en) 2000-09-12
PA8439101A1 (es) 2000-05-24
US20020147194A1 (en) 2002-10-10
CZ295141B6 (cs) 2005-05-18
UA56185C2 (uk) 2003-05-15
IS4985A (is) 1999-02-26
WO1998014433A1 (en) 1998-04-09
RS49699B (sr) 2007-12-31
CN1093123C (zh) 2002-10-23
DK0929528T3 (da) 2003-10-06
TW491842B (en) 2002-06-21
IL129045A (en) 2005-09-25
AU732451B2 (en) 2001-04-26
OA11002A (en) 2001-11-06
TNSN97161A1 (fr) 2005-03-15
IL129045A0 (en) 2000-02-17
CN1231661A (zh) 1999-10-13
BG64484B1 (bg) 2005-04-30
US20020091118A1 (en) 2002-07-11
PE2799A1 (es) 1999-02-04
AU3951497A (en) 1998-04-24
YU16899A (sh) 2002-03-18
GT199700107A (es) 1999-03-23
SA05260293B1 (ar) 2006-04-18
DE69723711T2 (de) 2004-02-05
US6627627B2 (en) 2003-09-30
EP0929528B1 (en) 2003-07-23
ATE245630T1 (de) 2003-08-15
AP9701107A0 (en) 1997-10-31
IL140623A (en) 2005-03-20
NZ334215A (en) 2000-09-29
US20020072519A1 (en) 2002-06-13
UY24730A1 (es) 2000-09-29
US6921760B2 (en) 2005-07-26
CN1329002A (zh) 2002-01-02
US6380186B1 (en) 2002-04-30
AR008861A1 (es) 2000-02-23
NO991525L (no) 1999-05-28
JP2000503679A (ja) 2000-03-28
IL140623A0 (en) 2002-02-10
NO991525D0 (no) 1999-03-29
MA26443A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
BR9713239A (pt) Lactamas e imidas heterocìclicas de aralquila e aralquileno
YU11997A (sh) Laktamski derivati i njihove farmaceutske kompozicije
BR9712959B1 (pt) nitratos orgánicos anti-trombóticos de inibidores da ace.
FI980341A0 (fi) 2-oksi-indolijohdannaisia
BR9909565A (pt) Derivados bicìclicos do ácido hidroxâmico
YU56995A (sh) Soli derivata indola
ES2137998T3 (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
RU94038064A (ru) Производные пиперазина и пиперидина, их применение в качестве противопсихотических средств, способ их получения фармацевтическая композиция
ES2128519T3 (es) Nuevas pirido-tiadiazinas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
FR2764800B1 (fr) Composition pharmaceutique solide contenant des derives de benzofuranne
EA200100774A1 (ru) Гетероциклические производные с функциональными группами (варианты), фармацевтическая композиция и комбинация, способ модулирования активности рецептора хемокина (варианты), способ профилактики инфицирования вич и лечения инфекции вич, замедления проявления спид и лечения спид, способ лечения воспалительных процессов
ES2107284T3 (es) Nuevas n-piridil-carboxamidas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
MC1476A1 (fr) Derives de la pyrrolidine
BR0012610A (pt) Novo derivado de difenilpiperidina
AU6319480A (en) 2-hydroxyalkyl-3,4,5-trihydroxypiperidines
ES2154830T3 (es) Derivados de 2-aminolactama n-(4-bencilo sustituida).
ES2103440T3 (es) Nuevas amidas y sulfonamidas naftalenicas, procedimiento de preparacion y composiciones farmaceuticas que las contienen.
GR1001597B (el) Νέα βιολογικώς δραστικά παράγωγα εμπουρναμενίνης, φαρμακευτικές συν?έσεις οι οποίες περιέχουν αυτά και μέ?οδος δια την παρασκευή αυτών.
ES2111871T3 (es) Nuevos derivados de aminoacidos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
TR200000153T2 (tr) İl-5 inhibite eden 6-azaurasil türevleri.
BR9611642A (pt) Compostos composição farmacéutica e processo para a preparação de compostos
DE59610175D1 (de) Hydantoinderivate als zwischenprodukte für pharmazeutische wirkstoffe
RU94038042A (ru) Производные гексагидроазепинов, фармацевтическая композиция на их основе и антипсихотропный агент
PE45195A1 (es) Derivado de aminoacido, procedimiento para su preparacion y composicion farmaceutica que lo contiene
BR9812160A (pt) Derivados de benzoxazina e benzotiazina e seu emprego em medicamentos

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements